Vera Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE, CA, 94005
Mailing Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE, CA, 94005
Phone
650-770-0077
Fiscal Year End
1231
EIN
812744449
Financial Overview
FY2025
$734.73M
Total Assets
$604.52M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | April 1, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 3 Initial insider ownership report | March 9, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 5, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Lead candidate atacicept's Phase 3 ORIGIN study for IgAN is on track for a critical top-line data readout in H2 2026.
- The company holds $210.5 million in cash, providing an estimated runway into mid-2027, supported by a $25 million loan draw.
Insider Trading
STRONG SELL
8 insiders
11 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.